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BRIEF REPORT
Clinical and Transcriptional Response to the Long-Acting Interleukin-1 Blocker
Canakinumab in Blau Syndrome–Related Uveitis
Gabriele Simonini,1 Zhaohui Xu,2 Roberto Caputo,1 Cinzia De Libero,1 Ilaria Pagnini,1 Virginia Pascual,2
and Rolando Cimaz1
Objective. To report on the clinical response to
canakinumab in a patient with sporadic nucleotide-
binding oligomerization domain–containing protein 2
(NOD-2)–associated pediatric granulomatous arthritis
(Blau syndrome) and severe resistant panuveitis, and to
describe gene expression profile changes throughout
such treatment.
Methods. A 4-year-old boy was diagnosed as
having Blau syndrome on the basis of typical clinical
features, histologic evidence of noncaseating granulo-
mas, and a NOD2 mutation. Ocular involvement was
initially controlled by topical and oral corticosteroids,
but over the years visual impairment and complica-
tions, such as macular edema and retinal detachment,
progressed. Ocular disease remained persistently active
despite treatment with multiple different immuno-
suppressants; therefore, canakinumab treatment was
started. Before and during the first 6 months of treat-
ment, the gene expression profile was determined each
month.
Results. Canakinumab treatment was well toler-
ated and led to rapid quiescence of uveitis, which had
been continuously active before this treatment. Gene
expression profiling analysis of the patient’s blood prior
to initiation of interleukin-1 (IL-1) blockade revealed
differential expression of 1,993 transcripts when com-
pared to healthy controls, and among the up-regulated
transcripts, pathway analysis showed that the pre-
dominant network consisted of innate immunity–related
transcripts. The transcriptional signature of the patient
overlapped with the transcriptional signature of pa-
tients with systemic-onset juvenile idiopathic arthritis,
and canakinumab treatment led to the normalization of
most of these transcriptional changes.
Conclusion. The pathogenesis of Blau syndrome
may be mediated by IL-1, and canakinumab may be
useful when this disorder is unresponsive to more con-
ventional treatments.
Sporadic nucleotide-binding oligomerization
domain–containing protein 2 (NOD-2)–associated pedi-
atric granulomatous arthritis (Blau syndrome) (MIM
ID #186580) is the genetic form of what was previously
known as early-onset sarcoidosis, now better defined as
pediatric granulomatous arthritis (1,2). It is character-
ized clinically by the triad of arthritis, skin rash, and
uveitis, and histologically by the presence of noncaseat-
ing epithelioid granulomas in the affected sites (3).
Genetic studies have shown that the disease is due to
mutations in the nucleotide-binding domain of the
NOD-2 (CARD-15) gene (4).
The course of the disease is variable, but in
many cases the prognosis is poor, with severe disabilities
and sequelae in a high percentage of patients (5). Eye
involvement is frequently progressive and can lead to
panuveitis and severe complications up to legal blind-
ness (5,6). The pathogenesis of Blau syndrome is not
well known, but the disease is believed to belong to the
spectrum of autoinflammatory disorders, for which
interleukin-1 (IL-1) inhibition is now an effective treat-
ment option.
Canakinumab is an anti–IL-1 monoclonal anti-
body that is effective in the treatment of cryopyrin-
associated periodic syndromes (7) and currently ap-
proved for that indication. Herein we report on the case
of a patient with Blau syndrome whom we have followed
up since early infancy (8). The patient developed sight-
threatening, drug-resistant panuveitis, which responded
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quite well to canakinumab. During the first 6 months of
treatment we also determined his gene expression pro-
file, which showed down-regulation of several IL-1–
related transcripts over time.
PATIENT AND METHODS
Case description. The patient, a 4-year-old boy, was
diagnosed as having Blau syndrome based on the manifesta-
tion of typical clinical features (ankle and wrist arthritis/
tenosynovitis, diffuse eczematous rash, and uveitis), histologic
evidence of noncaseating granulomas, and a heterozygous NOD2
mutation (p.R334W). Ocular involvement was initially con-
trolled by topical and oral corticosteroids, but over the years
visual impairment progressed. Other manifestations of Blau
syndrome (arthritis and rash) subsided over time. Bilateral
panuveitis progressed after age 5 years, and was initially
treated with methotrexate. However, ocular inflammation per-
sisted despite the addition of local steroid injections and
repeated intravenous (IV) bolus methylprednisolone treat-
ment; therefore, when the patient was age 10 years, infliximab
(initially at 5 mg/kg increased to 10 mg/kg IV every 4 to 6
weeks) was initiated. Although there was an initial improve-
ment, 1 year after this treatment was started uveitis worsened,
and at age 12 years infliximab was discontinued. Adalimumab
(24 mg/m2 every 2 weeks) was then initiated and the dosage of
methotrexate (15 mg/m2/weekly) was increased. However, ocu-
lar disease remained active. Mycophenolate mofetil (750 mg/
m2) and then abatacept (10 mg/kg/month IV) were sequen-
tially administered, without significant improvement.
At age 16 years the patient still had granulomatous
retinal lesions and anterior chamber inflammation, and mac-
ular edema developed, which led to retinal detachment. In
addition to the other steroid therapy, corticosteroid pulse
therapy was necessary to control disease flares, with an aver-
age of 3 boluses/month for 6 consecutive months. Because of
the supposed autoinflammatory nature of Blau syndrome, we
initiated a trial of IL-1 antibody administration (2 mg/kg/
month of canakinumab). During the 6 months that followed,
no ocular flare occurred and no steroid pulse therapy was
necessary. Concomitant treatment with oral methotrexate and
low-dose prednisone (0.2 mg/kg/day) remained unchanged.
Figure 1 shows fluorangiograms before treatment and after the
first 6 injections. The drug was well tolerated with no side
effects, and findings on laboratory tests (performed monthly)
were normal.
Methods. Blood was collected into Tempus Vacutainer
tubes (Applied Biosystems) during routine venipuncture be-
fore the first canakinumab injection and monthly thereafter for
5 months (immediately before the scheduled canakinumab
dose). Four demographically matched healthy subjects served
as controls. Parents provided informed consent to the study
authors and for the off-label use of the medication, and ap-
proval of the Meyer Children’s Hospital Ethics Committee was
also obtained. Total RNA was isolated from the whole blood
lysate using a MagMax total RNA extraction kit (Applied
Biosystems), and globin messenger RNA was removed with a
GLOBINclear Whole Blood Globin Reduction kit (Applied
Biosystems). RNA was further amplified and labeled with an
Illumina TotalPrep RNA Amplification kit (Applied Biosys-
tems). Complementary RNA was hybridized to a Human
HT12 V4 BeadChip array (IIlumina) and scanned on an
Illumina BeadStation 500. Fluorescent hybridization signals
were assessed with GenomeStudio software (Illumina).
After background subtraction and average normaliza-
Figure 1. Serial retinal angiograms showing the evolution of peripapillary granulomas in both eyes. Fluorescein angiography reveals severe leakage
from the granulomas before treatment, while after treatment the inflammatory leakage is reduced, although residual fluorescein staining in the
granulomas is still evident. A and B, Early-phase retinal angiography (at 43 seconds) (A) and late-phase retinal angiography (at 220 seconds) (B) of
the right eye, prior to canakinumab treatment. E and F, Early-phase retinal angiography (at 26 seconds) (E) and late-phase retinal angiography (at
231 seconds) (F) of the left eye, prior to canakinumab treatment. C and D, Early-phase retinal angiography (at 38 seconds) (C) and late-phase retinal
angiography (at 251 seconds) (D) of the right eye, after canakinumab treatment. G and H, Early-phase retinal angiography (at 48 seconds) (G) and
late-phase retinal angiography (at 267 seconds) (H) of the left eye, after canakinumab treatment.
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tion, microarray data were analyzed using GeneSpring 11.2
software (Agilent). Expression values of probes were log2-
transformed and normalized to the median value in healthy
controls. Fold change analysis was performed to compare the
patient samples with those of healthy controls. IPA (Ingenuity
Systems) was used to perform pathway analysis of the genes of
interest. For modular interpretation, a set of 260 transcrip-
tional modules was used as a preexisting framework for the
analysis. The approach used for the construction of such a
framework has been previously reported (9). Briefly, genes
with coordinate expression in whole blood within or across 9
disease data sets were selected in multiple rounds of clique and
paraclique clustering to form a 260–transcriptional module
framework. Within each module, the percentage of significant
Figure 2. Whole blood transcriptional profile of the patient with Blau syndrome compared to controls. A, Expression values of transcripts from 1
time point pretreatment and 1, 2, 3, 4, and 5 months after initiation of canakinumab therapy (V1–5) were log2 transformed and normalized to the
median value in 4 healthy controls. Fold change analysis of the sample from the untreated patient with Blau syndrome and 4 healthy controls resulted
in 1,993 differentially expressed transcripts. Hierarchical clustering of these probes was generated using the Pearson correlation method. B, Modular
analysis of samples from the patient with Blau syndrome was performed. The results revealed up-regulation of neutrophil and inflammation modules
and down-regulation of adaptive immune responses. A t-test was performed for each (baseline and followup) time point and for the healthy controls,
with an assumption of equal variance in an error model. Each column corresponds to 1 time point. Within each module, numbers of significant genes
were identified and their percentage represented as up-regulated or down-regulated. The transcript composition for each module has been described
elsewhere (9). DC  dendritic cell; NK  natural killer. In A and B, red signifies up-regulation and blue signifies down-regulation. C, In the sample
from the untreated patient with Blau syndrome, 496 up-regulated transcripts were analyzed by IPA. An inflammatory response network centered
around Toll-like receptor 2, inflammasome components, interleukin-1/interleukin-18 signaling, and neutrophil-encoded transcripts was predominant.
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probes was assessed by t-test with an assumption of equal
variance in an error model.
RESULTS
Gene expression profiling analysis of the patient’s
blood prior to initiation of IL-1 blockade revealed the
differential expression of 1,993 transcripts, in which 496
transcripts were up-regulated and 1,497 transcripts were
down-regulated (Figure 2A). Using our previously de-
scribed modular approach to data interpretation (9),
inflammation and interferon-inducible modules were
shown to be up-regulated, while adaptive immunity–
related modules were highly suppressed. Interestingly,
IL-1 blockade led to the normalization of most of these
transcriptional changes except for those related to neutro-
phils, for which up-regulation was maintained through-
out the followup period (Figure 2B). Among the up-
regulated transcripts, pathway analysis confirmed that
the predominant network consisted of innate immunity–
related transcripts (Figure 2C). Transcripts encoding
inflammasome-related molecules (i.e., AIM2, NLRC4,
NAIP, NLRP1, CASP4, and CASP5) were up-regulated
together with IL-1, Toll-like receptor 2, and neutrophil-
related transcripts.
To identify changes that could be specific to
NOD pathway dysregulation, we compared the tran-
scriptional profile of the patient’s blood at baseline
(prior to therapy) with the profiles of blood samples
from 21 patients with systemic-onset juvenile idiopathic
arthritis (JIA), a disease known to respond to IL-1
and/or IL-6 blockade (10,11). The transcriptional signa-
ture of the patient mostly overlapped with that of the
patients with systemic-onset JIA (Figure 3A). Among
transcripts that were up-regulated in the patient with
Blau syndrome but not in patients with systemic-onset
JIA, we identified a network centered around acyl-
coenzyme A oxidase 1, leptin receptor, and retinoic acid
receptor (RXRG), that normalized upon initiation of
IL-1 blockade (Figure 3B).
DISCUSSION
Blau syndrome is usually a progressive disorder,
which, if untreated, is often associated with severe
sequelae. In particular, ocular involvement can be dev-
astating and resistant to multiple treatments. Our pa-
tient had severe panuveitis, which did not respond to
treatment with corticosteroids or multiple different im-
munosuppressants, including infliximab, adalimumab,
mycophenolate mofetil, and abatacept, and which led to
retinal detachment at age 16 years. His disease required
repeated corticosteroid pulse therapy in order to control
frequent flares of posterior uveitis. Soon after the initi-
ation of canakinumab treatment, inflammatory eye in-
Figure 3. Whole blood transcriptional profile of the patient with untreated Blau syndrome overlaps with that of systemic-onset juvenile idiopathic
arthritis (SoJIA) patients. A, Expression values of transcripts from the patient with Blau syndrome at baseline (as in Figure 1A) were compared with
those from patients with systemic-onset JIA (normalized to values in 18 matched healthy controls). In this analysis, 1,560 transcripts were included
as they were common to the 2 Illumina bead array chips used in original analyses of Blau syndrome and systemic-onset JIA. As shown in the boxed
area, only 46 transcripts were up-regulated in Blau syndrome but not in systemic-onset JIA. B, The 46 genes were analyzed by IPA. A leptin
receptor–centered network was revealed. See Figure 2 for other definitions.
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volvement subsided and steroid pulse treatment, which
had been almost continuous for the previous 6 months,
was no longer needed.
The rationale for treating with canakinumab was
based on the presumed autoinflammatory nature of
Blau syndrome, as well as on a previous report that
noted clinical improvement in a patient with Blau syn-
drome who was treated with anakinra (12). In that study,
Arostegui et al also analyzed cytokine patterns, and
showed increased levels of IL-6 and tumor necrosis
factor (TNF) in plasma, and a slight increase in the
IL-1 level in the more severely affected patient, when
compared with controls. The patient was then treated
with anakinra, and analyses of cytokine levels in plasma
showed a marked decrease in IL-6, TNF, and IL-1
levels during treatment, which occurred simultaneously
with the patient’s clinical improvement. This therefore
suggests that IL-1 dysregulation might occur upstream
of IL-6 and TNF dysregulation in some patients with
Blau syndrome.
Moreover, there is some rationale for the use of
IL-1 in NOD-2–related disorders, since mutations in a
related gene (NLRP3) are responsible for excess IL-1
in cryopyrinopathies, and functional studies of the in-
flammasome have shown that caspase 1–mediated re-
lease of IL-1 also involves NOD-2 (13). However,
subsequent studies failed to demonstrate increased
IL-1 production by peripheral blood mononuclear cells
in patients with Blau syndrome, and anakinra was inef-
fective in 2 such patients (14,15). In both of these
studies, IL-1 in supernatants was measured by enzyme-
linked immunosorbent assay (ELISA), a less sensitive
method than whole blood gene expression profiling. The
difference between these 2 methods of cytokine detec-
tion has been evident in systemic-onset JIA as well,
where studies have failed to detect elevated IL-1 levels
by ELISA, while the role of this cytokine has been
proven by gene expression studies and clinical trials to
be important in the disease pathogenesis (10,16).
Our patient showed high expression levels of
innate immunity–related genes at baseline, and substan-
tial overlap with the profile of patients with systemic-
onset JIA, consistent with our hypothesis of an auto-
inflammatory, IL-1–responding disorder. Moreover,
almost all of these up-regulated transcripts normalized
after the first canakinumab injection. This normalization
remained stable during the months that followed, con-
comitant with the clinical improvement. The only mod-
ule that remained up-regulated through treatment was
the neutrophil-related module; we are not able to fully
explain this phenomenon but speculate that NOD2
mutation induces additional cytokine dysregulation,
other than dysregulation of IL-1, that might be respon-
sible for this.
Gene expression in Blau syndrome has been
rarely studied, and to our knowledge there is only one
such earlier report (17). This is the first study to
demonstrate the differential gene expression profile in
Blau syndrome at baseline and upon effective treatment
with canakinumab. To date, the patient has had 1 full
year of treatment, without further relapses of uveitis.
Given the lack of sustained response to all other treat-
ments received, and the temporal association of remis-
sion soon after initiation of canakinumab, together with
evidence of the rapid normalization of innate immunity–
related transcripts, we are confident that the disease
activity in this patient was due to excessive IL-1
production and that the use of IL-1 blockade is war-
ranted in this disease.
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